Gregory Gayle Moore

US Patent:

6584246, Jun 24, 2003

Filed:

Jul 5, 2000

Appl. No.:

09/610032

Inventors:

Ronald James Michal - Wrightwood CA
Gregory Scott Moore - Saugus CA
David Michael Rozelle - Woodland Hills CA
Fernando Torres - Valley Village CA

Assignee:

Litton Systems, Inc. - Woodland Hills CA

International Classification:

G02B 634

US Classification:

385 27, 372 6, 359341

Abstract:

A source, system and method for generating amplified stimulated emission is provided. The source includes a pump source for generating a pump light which is provided to a doped element, such as a doped fiber. Based on the pump light, the doped fiber, which may be a erbium doped fiber, generates the amplified stimulated emission. A coupler mechanism provides the pump light to the doped fiber and transmits the amplified stimulated emission from the doped fiber. The coupler mechanism isolates the pump light and the amplified stimulated emission using phase conditions. A system is also provided including a source and a sensor, such as a fiber optic gyroscope. A method for generating the amplified stimulated emission is further provided.

US Patent:

7592423, Sep 22, 2009

Filed:

May 30, 2006

Appl. No.:

11/421055

Inventors:

Jonathan Zalevsky - Riverside CA, US
Duc-Hanh Thi Nguyen - Sylmar CA, US
Gregory L. Moore - Monrovia CA, US
Sergei A. Ezhevsky - San Diego CA, US
John R. Desjarlais - Pasadena CA, US
Arthur J. Chirino - Camarillo CA, US
Darian Cash - Los Angeles CA, US
Matthew J. Bernett - Monrovia CA, US

Assignee:

Xencor, Inc. - Monrovia CA

International Classification:

C07K 14/00
C07K 1/00
C07K 17/00
C07K 16/00
A61K 38/24
A61K 38/27

US Classification:

530350, 530395, 530397, 530399

Abstract:

An adiponectin variant with one or more amino acid modifications relative to a corresponding parent adiponectin, wherein the adiponectin variant is not glycosylated, the adiponectin variant does not have residues 1-100 relative to human adiponectin, and wherein the solubility of the variant is improved by at least 3-fold relative to residues 110-244 of human adiponectin.

US Patent:

7678886, Mar 16, 2010

Filed:

May 30, 2006

Appl. No.:

11/421061

Inventors:

Jonathan Zalevsky - Riverside CA, US
Duc-Hanh Thi Nguyen - Sylmar CA, US
Gregory L. Moore - Monrovia CA, US
Sergei A. Ezhevsky - San Diego CA, US
John R. Desjarlais - Pasadena CA, US
Arthur J. Chirino - Camarillo CA, US
Darian Cash - Los Angeles CA, US
Matthew J. Bernett - Monrovia CA, US

Assignee:

Xencor, Inc. - Monrovia CA

International Classification:

C07K 14/00
C07K 1/00
C07K 17/00
C07K 16/00
A61K 38/24
A61K 38/27

US Classification:

530350, 530395, 530397, 530399

Abstract:

A composition comprising an adiponectin variant at a concentration of at least 2. 0 mg/mL, and a pharmaceutically acceptable carrier, wherein less than 20% of said adiponectin variant would aggregate after storage at 4 C. for one week in 10 mM PO, 150 mM NaCl buffer.

US Patent:

7709607, May 4, 2010

Filed:

May 30, 2006

Appl. No.:

11/421059

Inventors:

Jonathan Zalevsky - Riverside CA, US
Duc-Hanh Thi Nguyen - Sylmar CA, US
Gregory L. Moore - Monrovia CA, US
Sergei A. Ezhevsky - San Diego CA, US
John R. Desjarlais - Pasadena CA, US
Arthur J. Chirino - Camarillo CA, US
Darian Cash - Los Angeles CA, US
Matthew J. Bernett - Monrovia CA, US

Assignee:

Xencor, Inc. - Monrovia CA

International Classification:

C07K 1/00
C07K 14/00
C07K 16/00
C07K 17/00
A61K 38/24
A61K 38/27

US Classification:

530350, 530395, 530397, 530399

Abstract:

An adiponectin variant with one or more amino acid modifications relative to a corresponding parent adiponectin, wherein the solubility of the variant is improved by at least 3-fold relative to residues 110-244 of human adiponectin.

US Patent:

7749956, Jul 6, 2010

Filed:

May 30, 2006

Appl. No.:

11/421060

Inventors:

Jonathan Zalevsky - Riverside CA, US
Duc-Hanh Thi Nguyen - Sylmar CA, US
Gregory L. Moore - Monrovia CA, US
Sergei A. Ezhevsky - San Diego CA, US
John R. Desjarlais - Pasadena CA, US
Arthur J. Chirino - Camarillo CA, US
Darian Cash - Los Angeles CA, US
Matthew J. Bernett - Monrovia CA, US

Assignee:

Xencor, Inc. - Monrovia CA

International Classification:

A01N 37/18
A61K 38/16
A61K 38/00

US Classification:

514 2, 514 8, 514 21

Abstract:

A method of treating a mammal with an adiponectin mediated disorder comprising administering a therapeutically effective amount of an adiponectin variant with at least a 3-fold increased solubility relative to residues 110-244 of human adiponectin.

US Patent:

20070054359, Mar 8, 2007

Filed:

May 30, 2006

Appl. No.:

11/421062

Inventors:

Jonathan Zalevsky - Riverside CA, US
Duc-Hanh Nguyen - Sylmar CA, US
Gregory Moore - Monrovia CA, US
Sergei Ezhevsky - San Diego CA, US
John Desjarlais - Pasadena CA, US
Arthur Chirino - Camarillo CA, US
Darian Cash - Los Angeles CA, US
Matthew Bernett - Monrovia CA, US

International Classification:

C07K 14/475
C07K 14/52
C12P 21/06

US Classification:

435069100, 435320100, 435325000, 530399000

Abstract:

An adiponectin variant with at least a 3-fold increased solubility relative to residues -of human adiponectin, wherein the adiponectin variant has at least one covalently attached non-peptide moiety at at least one position selected from the group consisting of: A108, Y109, S146, D179, E220, R221, and L224, relative to human adiponectin